All data are based on the daily closing price as of December 12, 2025
s

ScinoPharm Taiwan

1789.TW
0.55 USD
0.00
0.00%

Overview

Last close
0.55 usd
Market cap
432.15M usd
52 week high
0.90 usd
52 week low
0.51 usd
Target price
0.57 usd

Valuation

P/E
71.0417
Forward P/E
N/A
Price/Sales
4.2239
Price/Book Value
1.2372
Enterprise Value
367.77M usd
EV/Revenue
3.611
EV/EBITDA
15.2617

Key financials

Revenue TTM
101.85M usd
Gross Profit TTM
36.39M usd
EBITDA TTM
20.94M usd
Earnings per Share
0.01 usd
Dividend
0.01 usd
Total assets
409.31M usd
Net debt
N/A usd

About

ScinoPharm Taiwan, Ltd., together with its subsidiaries, research and develops, produces, and sells active pharmaceutical ingredients (API) to pharmaceutical companies in Taiwan, rest of Asia, Europe, the America, and internationally. The company provides small molecular drugs, protein drugs, complex natural molecules and derivatives, synthesis services for biochemistry molecules, such as peptides and nucleic acids; generic API manufacturing services; outsourcing services. It offers CDMO services, such as contract analytical testing services, sterile injectables contract manufacturing, small molecules CDMO service, peptide CDMO service, and consulting services for the development and manufacturing of clinical, small-scale, and commercial-stage APIs and intermediates, as well as develops peptide synthesis technologies. In addition, the company develops and manufactures western medicines and other chemical materials, albumin and oligonucleotide medicines, and injections, as well as provides biological technology services, technical, and intellectual property rights related services. ScinoPharm Taiwan, Ltd. was incorporated in 1997 and is headquartered in Tainan City, Taiwan.
  • Symbol
    1789.TW
  • Exchange
    TW
  • Isin
    TW0001789006
  • Country
    Taiwan
  • Sector
    Healthcare
  • Industry
    Drug Manufacturers - Specialty & Generic
  • CEO
    Mr. Chih-Hsien Lo
  • Headquarter
    Tainan City
  • Web site
    https://www.scinopharm.com
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top